Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Conditions: Gastric Cancer; HER2-positive Gastric Cancer Interventions: Drug: Experimental; Drug: Control Sponsors: Gruppo Oncologico del Nord-Ovest Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Research